ProfileGDS5678 / 1455020_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 79% 78% 78% 79% 81% 80% 80% 79% 81% 80% 79% 79% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.3933378
GSM967853U87-EV human glioblastoma xenograft - Control 25.5675979
GSM967854U87-EV human glioblastoma xenograft - Control 35.3787978
GSM967855U87-EV human glioblastoma xenograft - Control 45.502778
GSM967856U87-EV human glioblastoma xenograft - Control 55.4891879
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.5535181
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.5258580
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.5884480
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.5109179
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.7717681
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.6986180
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.5166879
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.5389479
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.5211579